Common Variable Immunodeficiency Clinical Trial
OBJECTIVES: I. Determine whether polyethylene-glycol-conjugated interleukin 2 (PEG-IL-2) can
reduce the number of infections in patients with common variable immunodeficiency.
II. Determine whether this therapy can improve lung functions in these patients with
pulmonary impairment.
PROTOCOL OUTLINE: This is a randomized, open-label study. Patients are randomized to receive
polyethylene-glycol-conjugated interleukin 2 (PEG-IL-2) or placebo.
Patients receive PEG-IL-2 or placebo by subcutaneous injection weekly for 18 months.
Patients maintain a daily diary for 24 months.
Patients are followed every 4 months for 2 years.
Completion date provided represents the completion date of the grant per OOPD records
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03663933 -
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
|
Phase 2 | |
| Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
| Recruiting |
NCT05321407 -
COVID-19 Vaccine Responses in PIDD Subjects
|
||
| Recruiting |
NCT04339777 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
|
Phase 2 | |
| Completed |
NCT00542997 -
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
|
Phase 3 | |
| Completed |
NCT00168025 -
Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
|
Phase 3 | |
| Completed |
NCT00168012 -
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)
|
Phase 3 | |
| Completed |
NCT01196702 -
Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
|
||
| Recruiting |
NCT06355323 -
Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France
|
N/A | |
| Completed |
NCT00322556 -
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
|
Phase 3 | |
| Recruiting |
NCT02579967 -
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
|
Phase 2 | |
| Recruiting |
NCT06145100 -
Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)
|
||
| Completed |
NCT01289847 -
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
|
Phase 4 | |
| Completed |
NCT00520494 -
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
|
Phase 4 | |
| Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
| Completed |
NCT03211689 -
The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease
|
N/A | |
| Terminated |
NCT01489618 -
"Prime Boost" Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency
|
Phase 2 | |
| Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT03188419 -
Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide
|
||
| Not yet recruiting |
NCT05481554 -
Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency
|